Datashare
metadata only
Data and analysis code for paper: "Pre- and Postsynapses Contain Lecanemab-reactive Amyloid-beta in Post-mortem Human Alzheimer's Disease Brain
Recently, the amyloid beta (Ab) targeting antibody lecanemab has demonstrated modest therapeutic efficacy in slowing cognitive decline in people with Alzheimer’s disease (AD). Lecanemab clears amyloid plaques from the brain, however, plaque load does not correlate strongly with cognitive function. T
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Nilotinib in Huntington's Disease#1031552
- Comparative effects of some pharmacological and non-pharmacological interventions on cognitive function in Alzheimer’s disease: A Bayesian network meta-analysis.#67528
- Network-Level Mechanisms for Preclinical Alzheimer's Disease Development#865911
- The Effect of Oral Use of Lyophilised Royal Jelly on Cognitive Functions and Immune System in Elderly Individuals#1295412
- Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya#833861
Record · ID 1279203
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive